IF 2.6 4区 医学 Q3 INFECTIOUS DISEASES
Kai Ming Chow, Siu Kwan Wo, Simon Wai Yin So, Phyllis Mei Shan Cheng, Keary Rui Zhou, Wai Li Lim, Joan Zhong Zuo, Philip Kam Tao Li
{"title":"Stability of Daptomycin in Dextrose and Icodextrin-Based Peritoneal Dialysis Solutions.","authors":"Kai Ming Chow, Siu Kwan Wo, Simon Wai Yin So, Phyllis Mei Shan Cheng, Keary Rui Zhou, Wai Li Lim, Joan Zhong Zuo, Philip Kam Tao Li","doi":"10.1155/cjid/5553355","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> With emerging antibiotic resistance, many patients on peritoneal dialysis require newer antibiotic treatment such as daptomycin. Inadequate clinical information exists across different peritoneal dialysis solutions, including icodextrin, for the stability of intraperitoneal daptomycin. To guide the clinical practice of intraperitoneal daptomycin treatment, we need to establish the stability of daptomycin at dextrose concentration higher than 1.5% and icodextrin, as well as the duration of stability. <b>Methods:</b> We tested the stability of daptomycin in three types of peritoneal dialysis bags (UltraBag dextrose 2.5%, UltraBag icodextrin 7.5%, and Stay-Safe Balance 2.3%). Daptomycin was reconstituted with water for injection (50 mg/mL), followed by administration to peritoneal dialysis bags to obtain the final daptomycin concentrations of 70 μg/mL (equivalent to 140 mg/2L, the maintenance level) and 245 μg/mL (equivalent to 490 mg/2L, the loading level). The bags were then placed at ambient temperature (25°C) followed by withdrawing 5 mL samples at 0, 4, 8, 12, 24, and 48 h for UltraBag dextrose 2.5% and UltraBag icodextrin 7.5% and 0, 4, 8, 12, and 24 h for Stay-Safe Balance 2.3%. The concentrations of daptomycin in the collected samples were quantified by high-performance liquid chromatography with diode array detector (HPLC-DAD). <b>Results:</b> Under ambient condition, daptomycin was stable at maintenance level in UltraBag dextrose 2.5% for 48 h and in UltraBag icodextrin 7.5% or Stay-Safe Balance 2.3% for 24 h. For loading level, daptomycin was stable in UltraBag dextrose 2.5% and Stay-Safe Balance 2.3% for 12 h and in UltraBag icodextrin 7.5% for 48 h. <b>Conclusions:</b> Current stability results support and guide the use of intraperitoneal daptomycin in different dialysis solutions. Patients with peritonitis requiring icodextrin exchange and assisted preparation of daptomycin can benefit from nurses who provide daily home visit based on our stability results.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":"2025 ","pages":"5553355"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968160/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Infectious Diseases & Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/cjid/5553355","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:随着抗生素耐药性的出现,许多腹膜透析患者需要使用新的抗生素治疗,如达托霉素。关于腹膜内注射达托霉素的稳定性,不同腹膜透析液(包括冰冻糊精)的临床资料不足。为了指导腹膜内达托霉素治疗的临床实践,我们需要确定达托霉素在葡萄糖浓度高于1.5%和冰冻糊精时的稳定性以及稳定性的持续时间。方法我们测试了达托霉素在三种腹膜透析袋(UltraBag 葡萄糖 2.5%、UltraBag 冰糊精 7.5% 和 Stay-Safe Balance 2.3%)中的稳定性。用注射用水重组达托霉素(50 毫克/毫升),然后将其注入腹膜透析袋,以获得 70 微克/毫升(相当于 140 毫克/2 升,维持水平)和 245 微克/毫升(相当于 490 毫克/2 升,负荷水平)的最终达托霉素浓度。然后将袋子放置在环境温度(25°C)下,分别在 0、4、8、12、24 和 48 小时内抽取 5 mL 样品(UltraBag 葡萄糖 2.5% 和 UltraBag 冰糊精 7.5%),在 0、4、8、12 和 24 小时内抽取 5 mL 样品(Stay-Safe Balance 2.3%)。收集到的样品中的达托霉素浓度通过高效液相色谱-二极管阵列检测器(HPLC-DAD)进行定量。检测结果在环境条件下,达托霉素在UltraBag葡萄糖2.5%中的维持水平稳定48小时,在UltraBag冰糊精7.5%或Stay-Safe Balance 2.3%中的维持水平稳定24小时;在负载水平下,达托霉素在UltraBag葡萄糖2.5%和Stay-Safe Balance 2.3%中的维持水平稳定12小时,在UltraBag冰糊精7.5%中的维持水平稳定48小时:目前的稳定性结果支持并指导在不同透析液中使用腹腔注射达托霉素。根据我们的稳定性结果,需要更换冰糊精和辅助制备达托霉素的腹膜炎患者可从护士的每日家访中获益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Stability of Daptomycin in Dextrose and Icodextrin-Based Peritoneal Dialysis Solutions.

Background: With emerging antibiotic resistance, many patients on peritoneal dialysis require newer antibiotic treatment such as daptomycin. Inadequate clinical information exists across different peritoneal dialysis solutions, including icodextrin, for the stability of intraperitoneal daptomycin. To guide the clinical practice of intraperitoneal daptomycin treatment, we need to establish the stability of daptomycin at dextrose concentration higher than 1.5% and icodextrin, as well as the duration of stability. Methods: We tested the stability of daptomycin in three types of peritoneal dialysis bags (UltraBag dextrose 2.5%, UltraBag icodextrin 7.5%, and Stay-Safe Balance 2.3%). Daptomycin was reconstituted with water for injection (50 mg/mL), followed by administration to peritoneal dialysis bags to obtain the final daptomycin concentrations of 70 μg/mL (equivalent to 140 mg/2L, the maintenance level) and 245 μg/mL (equivalent to 490 mg/2L, the loading level). The bags were then placed at ambient temperature (25°C) followed by withdrawing 5 mL samples at 0, 4, 8, 12, 24, and 48 h for UltraBag dextrose 2.5% and UltraBag icodextrin 7.5% and 0, 4, 8, 12, and 24 h for Stay-Safe Balance 2.3%. The concentrations of daptomycin in the collected samples were quantified by high-performance liquid chromatography with diode array detector (HPLC-DAD). Results: Under ambient condition, daptomycin was stable at maintenance level in UltraBag dextrose 2.5% for 48 h and in UltraBag icodextrin 7.5% or Stay-Safe Balance 2.3% for 24 h. For loading level, daptomycin was stable in UltraBag dextrose 2.5% and Stay-Safe Balance 2.3% for 12 h and in UltraBag icodextrin 7.5% for 48 h. Conclusions: Current stability results support and guide the use of intraperitoneal daptomycin in different dialysis solutions. Patients with peritonitis requiring icodextrin exchange and assisted preparation of daptomycin can benefit from nurses who provide daily home visit based on our stability results.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
108
审稿时长
>12 weeks
期刊介绍: Canadian Journal of Infectious Diseases and Medical Microbiology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to infectious diseases of bacterial, viral and parasitic origin. The journal welcomes articles describing research on pathogenesis, epidemiology of infection, diagnosis and treatment, antibiotics and resistance, and immunology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信